Physician profile
Earl E Holmstead
NPI 1790870400
$1,512.73
in general payments reported to CMS, 2019-2025
24 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $117 · 2021: $272 · 2022: $243 · 2023: $170 · 2024: $315 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $447.25 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $224.83 | 2019-2025 | Trelegy Ellipta |
| Abbvie INC. | $114.07 | 2021-2024 | |
| Medtronic, INC. | $97.05 | 2021-2023 | Minimed 770g |
| Novo Nordisk INC | $85.73 | 2019-2025 | |
| Pfizer INC. | $81.59 | 2019-2024 | |
| Amarin Pharma, INC. | $62.63 | 2020-2021 | |
| Exact Sciences Corporation | $53.13 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $52.20 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $43.79 | 2021-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $28.59 | 2021-2025 | Rotateq, Capvaxive, M-M-R II |
| Boston Scientific Corporation | $28.37 | 2022-2025 | General - Pain Management |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.70 | 2021 | |
| Dexcom, INC. | $21.93 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $18.88 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $18.11 | 2023 | Amvuttra |
| Janssen Pharmaceuticals, INC | $18.01 | 2023 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $16.22 | 2021 | |
| Alfasigma USA, INC. | $14.00 | 2020 | |
| Jazz Pharmaceuticals INC. | $13.71 | 2021 | |
| Abbott Laboratories | $13.43 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.22 | 2022 | |
| Stimwave Technologies Incorporated | $11.69 | 2022 | |
| Medtronic USA, INC. | $11.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Earl Holmstead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.